Comprehensive assessment of the pharmacokinetic properties of a single bolus dose of colecalciferol in terms of efficacy and safety

Background: The lack of a unified approach to the treatment of deficiency and vitamin D deficiency stimulated a detailed study of the dynamics of indicators of phosphorus-calcium metabolism, parathyroid hormone, 25(OH)D (calcidiol).

Aim: To evaluate the pharmacokinetic properties of colecalciferol at a dosage of 150 000 IU, from the standpoint of its efficacy and safety in clinical practice.

Materials and methods: Observational, single-center, prospective, selective, uncontrolled study of a comprehensive assessment of the pharmacokinetic properties of a single saturating dose of 150 000 IU of colecalciferol. To assess the pharmacokinetic properties of colecalciferol at a dosage of 150 000 IU, we set efficacy and safety criteria. The criterion for the effectiveness of treatment was to achieve an adequate level of vitamin D (more than 30 ng / ml at the initial insufficient level and more than 20 ng / ml for patients with vitamin D deficiency). The safety criteria for the correction of vitamin D deficiency or deficiency were the absence of patient complaints, adverse events and / or serious adverse events, as well as the preservation of the main laboratory parameters of phosphorus-calcium metabolism within the reference values.

Results: When studying the efficacy of a dose of 150 000 IU in patients with vitamin D deficiency and insufficiency, it was found that the level of calcidiol was significantly higher in the group after treatment with colecalciferol compared with the group before treatment (p <0.05). The peak of the maximum value for patients with deficiency was established on the 14 day from the moment of administration of colecalciferol and was 37.1 ± 6.28 ng / ml, and for patients with initial vitamin D deficiency 40.1 ± 3.71 ng / ml. In the study of the safety of colecalciferol in a bolus dose of 150 000 IU, there were no statistically significant differences in the laboratory parameters of calcium-phosphorus metabolism, both in the group before treatment and after correction of deficiency and vitamin D insufficiency in both groups.

Conclusion: Colecalciferol in the form of a single bolus dose of 150 000 IU demonstrated its efficacy and safety in real clinical practice.

Vitamin D, colecalciferol, treatment, efficacy, safety, pharmacokinetics

1. Holick MF. Vitamin D Deficiency. N. Engl. J. Med. 2007;357(3):266-281. doi: https://doi.org/10.1056/NEJMra070553

2. Mithal A. Treatment of vitamin D deficiency. Endocrine case management. In: Proceedings of ICE/ENDO 2014 Meeting. Chicago, USA; 2014. p. 37-39

3. Scragg R, Waayer D, Stewart AW, et al. The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. The Journal of Steroid Biochemistry and Molecular Biology. 2016;164:318-325. doi: https://doi.org/10.1016/j.jsbmb.2015.09.010

4. Medicine Io. Dietary Reference Intakes for Calcium and Vitamin D. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Washington, DC: The National Academies Press; 2011. 1132 p.

5. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых // Проблемы Эндокринологии. - 2016. - Т. 62. - №4. - C. 60-84. [Pigarova EA, Rozhinskaya LY, Belaya JE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60. (In Russ).] doi: https://doi.org/10.14341/probl201662460-84

6. Schleck M-L, Souberbielle J-C, Jandrain B, et al. A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency. Nutrients. 2015;7(7):5413-5422. doi: https://doi.org/10.3390/nu7075227

7. Meekins ME, Oberhelman SS, Lee BR, et al. Pharmacokinetics of daily versus monthly vitamin D3 supplementation in non-lactating women. Eur. J. Clin. Nutr. 2014;68(5):632-634. doi: https://doi.org/10.1038/ejcn.2013.278

8. Ilahi M, Armas LAG, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. The American Journal of Clinical Nutrition. 2008;87(3):688-691. doi: https://doi.org/10.1093/ajcn/87.3.688

9. Glendenning P, Zhu K, Inderjeeth C, et al. Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: A randomized controlled trial. J. Bone Miner. Res. 2012;27(1):170-176. doi: https://doi.org/10.1002/jbmr.524

10. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. The Lancet Diabetes & Endocrinology. 2018;6(11):847-858. doi: https://doi.org/10.1016/s2213-8587(18)30265-1

11. Khaw K-T, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. The Lancet Diabetes & Endocrinology. 2017;5(6):438-447. doi: https://doi.org/10.1016/s2213-8587(17)30103-1

12. Dudenkov DV, Yawn BP, Oberhelman SS, et al. Changing Incidence of Serum 25-Hydroxyvitamin D Values Above 50 ng/mL: A 10-Year Population-Based Study. Mayo Clin. Proc. 2015;90(5):577-586. doi: https://doi.org/10.1016/j.mayocp.2015.02.012

13. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern. Med. Rev. 2008;13(1):6-20.

14. Cranney A, Horsley T, O’Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep). 2007(158):1-235

15. Leidig-Bruckner G, Roth HJ, Bruckner T, et al. Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels—an observational study during clinical practice conditions. Osteoporos. Int. 2010;22(1):231-240. doi: https://doi.org/10.1007/s00198-010-1214-5

16. Scragg R, Waayer D, Stewart AW, et al. The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. The Journal of Steroid Biochemistry and Molecular Biology. 2016;164:318-325. doi: https://doi.org/10.1016/j.jsbmb.2015.09.010

17. Scragg R, Stewart AW, Waayer D, et al. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study. JAMA Cardiology. 2017;2(6):608. doi: https://doi.org/10.1001/jamacardio.2017.0175

18. Scragg R, Khaw K-T, Toop L, et al. Monthly High-Dose Vitamin D Supplementation and Cancer Risk. JAMA Oncology. 2018;4(11):e182178. doi: https://doi.org/10.1001/jamaoncol.2018.2178

19. Soe HHK, Abas ABL, Than NN, et al. Vitamin D supplementation for sickle cell disease. Cochrane Database Syst Rev. 2017. doi: https://doi.org/10.1002/14651858.CD010858.pub2